Dr. Weber Discusses Updated Data for CheckMate-238

Video

In Partnership With:

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses updated data for the Checkmate-238 trial.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses updated data for the Checkmate-238 trial.

This phase III study tests adjuvant therapy with nivolumab (Opdivo) versus ipilimumab (Yervoy) for patients with complete resection of stage III/IV melanoma. Initial results showed clear benefit under the nivolumab arm compared with ipilimumab, with significantly less toxicity. Six additional months of follow-up indicate that nivolumab improves recurrence-free survival (RFS), which was the trial’s primary endpoint. The proportion of patients under nivolumab arms who had stop therapy from adverse events was 8% compared with greater than 30% of those who were on the ipilimumab arms.

After 24 total months of follow-up, RFS was 63% for patients treated with nivolumab versus 50% for ipilimumab. Weber adds that metastases-free survival also showed a clear advantage for nivolumab.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD